ArticleEMBO molecular medicine2013
Urine proteomics for discovery of improved diagnostic markers of Kawasaki disease.
Article in EMBO molecular medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 92 citations in OpenAlex.
- Serum meprin α levels for the detection of systemic inflammatory response syndrome.Molecular medicine (Cambridge, Mass.) · 2026Article
- Plasma Exosomal-Derived SERPINA1 and GNAI2 Downregulation as Potential Diagnostic Biomarkers of Kawasaki Disease with Coronary Artery Aneurysms.International journal of molecular sciences · 2025Article
- Urinary Proteome and Exosome Analysis Protocol for the Discovery of Respiratory Diseases Biomarkers.Biomolecules · 2025Article
- Kawasaki disease: insights into the roles of T cells.Frontiers in immunology · 2025Review
- Multisystem inflammatory syndrome in children and Kawasaki disease.Frontiers in immunology · 2025Review
- Using CSF Proteomics to Investigate Herpesvirus Infections of the Central Nervous System.Viruses · 2022Article
- Many kinds of oxidized proteins are present more in the urine of the elderly.Clinical proteomics · 2022Article
- Urine Proteomics for Noninvasive Monitoring of Biomarkers in Bronchopulmonary Dysplasia.Neonatology · 2022Article
- The Relationship Between Lipoprotein-Associated Phospholipase-A2 and Coronary Artery Aneurysm in Children With Kawasaki Disease.Frontiers in pediatrics · 2022Article
- MicroRNA-197-3p mediates damage to human coronary artery endothelial cells via targeting TIMP3 in Kawasaki disease.Molecular and cellular biochemistry · 2021Article
- Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets.Nature communications · 2021Article
- Urinary proteome profiling for stratifying patients with familial Parkinson's disease.EMBO molecular medicine · 2021Article
- To be there when the picture is being painted.The Journal of biological chemistry · 2020Article
- Urine proteome of COVID-19 patients.Urine (Amsterdam, Netherlands) · 2020Article
- The Platelet microRNA Profile of Kawasaki Disease: Identification of Novel Diagnostic Biomarkers.BioMed research international · 2020Article
- Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor.JCI insight · 2019Article
- Clinical potential of mass spectrometry-based proteogenomics.Nature reviews. Clinical oncology · 2019Review
- New biomarkers of Kawasaki disease identified by urine proteomic analysis.FEBS open bio · 2019Article
- Phosphorylated proteomics analysis of human coronary artery endothelial cells stimulated by Kawasaki disease patients serum.BMC cardiovascular disorders · 2019Article
- Biomarkers for Kawasaki Disease: Clinical Utility and the Challenges Ahead.Frontiers in pediatrics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
Abstract
Kawasaki disease (KD) is a systemic vasculitis of unknown etiology. Absence of definitive diagnostic markers limits the accuracy of clinical evaluations of suspected KD with significant increases in morbidity. In turn, incomplete understanding of its molecular pathogenesis hinders the identification of rational targets needed to improve therapy. We used high-accuracy mass spectrometry proteomics to analyse over 2000 unique proteins in clinical urine specimens of patients with KD. We discovered that urine proteomes of patients with KD, but not those with mimicking conditions, were enriched for markers of cellular injury such as filamin and talin, immune regulators such as complement regulator CSMD3, immune pattern recognition receptor muclin, and immune cytokine protease meprin A. Significant elevations of filamin C and meprin A were detected in both the serum and urine in two independent cohorts of patients with KD, comprised of a total of 236 patients. Meprin A and filamin C exhibited superior diagnostic performance as compared to currently used markers of disease in a blinded case-control study of 107 patients with suspected KD, with receiver operating characteristic areas under the curve of 0.98 (95% confidence intervals [CI] of 0.97-1 and 0.95-1, respectively). Notably, meprin A was enriched in the coronary artery lesions of a mouse model of KD. In all, urine proteome profiles revealed novel candidate molecular markers of KD, including filamin C and meprin A that exhibit excellent diagnostic performance. These disease markers may improve the diagnostic accuracy of clinical evaluations of children with suspected KD, lead to the identification of novel therapeutic targets, and allow the development of a biological classification of Kawasaki disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.